New state-of-the-art advanced therapies testing laboratories provide additional capacity for the growing cell and gene therapy industry. WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, has opened its advanced therapies testing facility at 400 Rouse Boulevard in Philadelphia’s Navy Yard. The new facility, which includes 140,000 square feet laboratories, will further …Read More >
In recent years, the demand for cell and gene therapy has increased substantially. With the success in gene and cell therapy has also increased demand for plasmid DNA. In supplying the industry with high-quality Plasmid DNA, key prominent market challenges are capacity availability, accelerated TAT and affordability. In this presentation, WuXi Advanced Therapies will …Read More >
Developing innovative advanced therapies is one of our greatest opportunities to dramatically improve patients’ lives. WuXi Advanced Technologies recently announced the expansion of its service capabilities by offering a fully integrated CAR-T cell therapy platform to help accelerate the timeline for cell and gene therapy development, manufacturing, and release while providing greater predictability. This …Read More >
The field of gene therapy has experienced significant growth in recent years. Adeno-associated virus (AAV)–mediated therapies account for ~70% of the gene therapy market. However, the manufacturing capacity for AAV vectors remains a critical bottleneck. WuXi Advanced Therapies launched a world-class AAV suspension platform early 2020. In this webinar, we will reveal the improvements that …Read More >
In January, Phacilitate Leaders World & World Stem Cell Summit 2020 brought together the entire ecosystem of the advanced therapies industry from all corners of the globe to continue to build strong partnerships and collaborations to Miami, FL. With so many great topics covered, common theme was innovation in research through to manufacturing and commercialization. …Read More >